Literature DB >> 8882472

Clinical features of ulcerative colitis in Korea.

S M Park1, D S Han, S K Yang, W S Hong, Y I Min.   

Abstract

OBJECTIVES: This study was conducted to investigate the clinical features of ulcerative colitis in Korea and to evaluate the clinical course after medical therapy.
METHODS: Symptoms, signs and results of the treatment were retrospectively analyzed in 66 patients (male 32, female 34) diagnosed to have ulcerative colitis at the Asan Medical Center.
RESULTS: The median age of the beginning of symptoms was 36 years (range, 14-72). Diarrhea and rectal bleeding were observed in 95.1 and 91.4%, respectively, at the time of diagnosis, while extra-colonic manifestations were observed in 24.1%. In 41 patients (62.1%), colitis developed in the rectum and sigmoid colon, while left colitis and extensive colitis developed in 11 (16.7%) and 14 patients (21.2%), respectively. The severity of disease was determined according to the clinical criteria, resulting in 22 (33.3%) mild, 21 (31.8%) moderate and 23 (34.8%) severe diseases. The seventy was also classified as 1, 2 and 3 by sigmoidocolonoscopic findings: 1;17 patients(25.8%), 2;27(40.9%) and 22(33.3%). Among 23 patients with severe disease, 5 patients (7.6%) received total colectomy due to toxic megacolon, intractability to medical therapy, ileocolic fistula and intestinal stenosis. The severity determined by colonoscopic findings was well correlated with that determined clinically and was closely related to the severity of symptoms, levels of albumin, hemoglobin and the count of leukocyte. The median duration of symptoms before treatment was 4 weeks (range, 11-300). All patients were treated with sulfasalazine and prednisolone. All patients with medical therapy, except 2 patients (96.7%), obtained clinical remission. The median days required for remission was 14 (range, 3-70). Relapse rates at 6 months, 1 year and 2 years after the initiation of treatment were 19.7, 34.1 and 49.3%, respectively. The median disease-free interval from the time of remission was 10 months (range, 2-60). After remission, the subsequent relapse rate increased in severe disease, while no difference was observed between the disease extents.
CONCLUSIONS: The general characteristics of clinical manifestations and clinical course, after the medical treatment of ulcerative colitis in Korean patients, are not considerably different from those in Western countries.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8882472      PMCID: PMC4532005          DOI: 10.3904/kjim.1996.11.1.9

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  19 in total

1.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

Review 2.  Etiology of inflammatory bowel diseases: where have we been? Where are we going?

Authors:  G Gitnick
Journal:  Scand J Gastroenterol Suppl       Date:  1990

3.  Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity.

Authors:  F Shanahan; R H Duerr; J I Rotter; H Yang; L R Sutherland; C McElree; C J Landers; S R Targan
Journal:  Gastroenterology       Date:  1992-08       Impact factor: 22.682

4.  Ulcerative colitis: one disease or two? (Quantitative histological differences between distal and extensive disease).

Authors:  D Jenkins; A Goodall; B B Scott
Journal:  Gut       Date:  1990-04       Impact factor: 23.059

5.  Why do patients with ulcerative colitis relapse?

Authors:  S A Riley; V Mani; M J Goodman; S Lucas
Journal:  Gut       Date:  1990-02       Impact factor: 23.059

6.  Course of ulcerative colitis: analysis of changes in disease activity over years.

Authors:  E Langholz; P Munkholm; M Davidsen; V Binder
Journal:  Gastroenterology       Date:  1994-07       Impact factor: 22.682

7.  Extracolonic diagnoses in ulcerative colitis: an epidemiological study.

Authors:  U Monsén; J Sorstad; G Hellers; C Johansson
Journal:  Am J Gastroenterol       Date:  1990-06       Impact factor: 10.864

8.  Nonspecific proctocolitis in northeastern Scotland: a community study.

Authors:  T S Sinclair; P W Brunt; N A Mowat
Journal:  Gastroenterology       Date:  1983-07       Impact factor: 22.682

9.  Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987.

Authors:  E Langholz; P Munkholm; O H Nielsen; S Kreiner; V Binder
Journal:  Scand J Gastroenterol       Date:  1991-12       Impact factor: 2.423

10.  Immune activation genes in inflammatory bowel disease.

Authors:  T Matsuura; G A West; K R Youngman; J S Klein; C Fiocchi
Journal:  Gastroenterology       Date:  1993-02       Impact factor: 22.682

View more
  2 in total

1.  Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis.

Authors:  Han Ho Jeon; Hyun Jung Lee; Hui Won Jang; Jin Young Yoon; Yoon Suk Jung; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

2.  Renal involvement in children and adolescents with inflammatory bowel disease.

Authors:  Hea Min Jang; Hee Sun Baek; Jung-Eun Kim; Ju Young Kim; Yeon Hee Lee; Hee Yeon Cho; Yon Ho Choe; Ben Kang; Byung-Ho Choe; Bong Seok Choi; Min Hyun Cho
Journal:  Korean J Pediatr       Date:  2018-09-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.